Comparison of Olmesartan Medoxomil Versus Amlodipine Besylate on Regression of Ventricular and Vascular Hypertrophy-Reference-Cited by-同舟云学术

Comparison of Olmesartan Medoxomil Versus Amlodipine Besylate on Regression of Ventricular and Vascular Hypertrophy

Published:2009-08 Issue:3 Volume:104 Page:359-365
ISSN:0002-9149
Container-title:The American Journal of Cardiology
language:en
Short-container-title:The American Journal of Cardiology

Author:

Rosendorff Clive,Dubiel Robert,Xu Jianbo,Chavanu Kathleen J.

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference12 articles.

1. 2007 Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC);Mancia;Eur Heart J,2007

2. Calcium channel blockers in the spectrum of antihypertensive agents;Liebson;Expert Opin Pharmacother,2006

3. Is angiotensin II a direct mediator of left ventricular hypertrophy?;Reudelhuber;Hypertension,2007

4. Pharmacology of CS-866, a novel nonpeptide angiotensin II receptor antagonist;Mizuno;Eur J Pharmacol,1995

5. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial;Devereux;Circulation,2004

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of amlodipine on clinical outcomes for heart failure in patients with dilated cardiomyopathy: a Korean nationwide cohort study;Frontiers in Cardiovascular Medicine;2023-11-17

2. Regression of cardiac hypertrophy in health and disease: mechanisms and therapeutic potential;Nature Reviews Cardiology;2023-01-04

3. Effect of amlodipine on ventricular hypertrophy in hypertension patients: a systematic review and meta-analysis;Annals of Palliative Medicine;2021-10

4. The role of renin–angiotensin–aldosterone system inhibition in the regression of hypertensive left ventricular hypertrophy: the evidence of the last three decades;Drugs & Therapy Perspectives;2020-08-27

5. Comparative effectiveness of an angiotensin receptor blocker, olmesartan medoxomil, in older hypertensive patients;The Journal of Clinical Hypertension;2018-02